Prevention of venous thromboembolism in pregnancy

Best Practice and Research: Clinical Haematology

Volumn 16, Issue 2, 2003, Pages 261-278

  Greer, Ian A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Heparin; Low molecular weight heparin; Pregnancy; Thrombophilia; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; DALTEPARIN; DEXTRAN; ENOXAPARIN; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; COUMARIN;

AGE DISTRIBUTION; ANAPHYLAXIS; BODY MASS; CAUSE OF DEATH; CESAREAN SECTION; CLINICAL TRIAL; COMPRESSION THERAPY; DEEP VEIN THROMBOSIS; DEVELOPED COUNTRY; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG SAFETY; EMERGENCY SURGERY; FAMILY HISTORY; FEMALE; HUMAN; IDIOPATHIC DISEASE; LUNG EMBOLISM; MATERNAL MORTALITY; OSTEOPOROSIS; PATHOLOGIC FRACTURE; POSTTHROMBOSIS SYNDROME; PREGNANCY DISORDER; PRIORITY JOURNAL; PUERPERIUM; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; VAGINAL DELIVERY; CONGENITAL DISORDER; DISEASE ASSOCIATION; EMBRYOPATHY; INCIDENCE; MATERNAL MORBIDITY; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION; VENOUS THROMBOEMBOLISM;

EID: 0037642238     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)00095-6     Document Type: Review

References (70)

1. Clinical Excellence, Scottish Executive Health Department and Department of Health, Social Services and Public Safety: Northern Ireland, Confidential enquiries into maternal deaths in the United Kingdom 1997-1999. London: TSO, 2001.
2. Macklon NS & Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scottish Medical Journal 1996; 41: 83-86.
3. Rutherford S, Montoro M, McGhee W & Strong T. Thromboembolic disease associated with pregnancy: an II year review (abstract). American Journal of Obstetrics & Gynecology 1991; 164(supplement): 286.
4. McColl M, Ramsay JE, Tait RC et al. Risk factors for pregnancy associated venous thromboembolism. Thrombosis & Haemostasis 1997; 78: 1183-1188.
5. Kodama H, Fukuda J, Karube H et al. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertility & Sterility 1996; 3: 417-424.
6. Levy D, Gompel A & Conard J. Ovarian hyperstimulation and thrombosis. In Brenner B, Marder VJ & Conard J (eds) Womens Issues in Thrombosis and Haemostasis. London: Martin Dunitz, 2002, pp 143-150.
7. Roopen A, Hassan A, Shehata HA et al. Internal jugular vein thrombosis after assisted conception therapy. British Journal of Haematology 2001; 115: 153-155.
8. McColl M, Ellison J, Greer IA et al. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism. British Journal of Haematology 2000; 108: 272-274.
9. Bergqvist D, Bergqvist A, Lindhagen A et al. Long-term outcome of patients with venous thromboembolism during pregnancy. In: Greer IA, et al., editors. Haemostasis and thrombosis in obstetrics and gynaecology. London: Chapman & Hall. p. 349-60, 1992.
10. Clarke P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thrombosis & Haemostasis 1998; 79: 1166-1170.
11. Greer IA. Haemostasis and thrombosis in pregnancy. In Bloom AL, Forbes CD, Thomas DP & Tuddenham EGD (eds) Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1994, pp 987-1015.
12. Macklon NS, Greer IA & Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. British Journal of Obstetrics & Gynaecology 1997; 104: 191-197.
13. Macklon NS & Greer IA. The deep leg venous system in the puerperium. An ultrasound study. British Journal of Obstetrics & Gynaecology 1997; 104: 198-200.
14. Lindhagen A, Bergqvist A, Bergqvist D & Hallbook T. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy. British Journal of Obstetrics & Gynaecology 1986; 93: 348-352.
15. Walker ID. Congenital thrombophilia. Baillière's Clinical Obstetrics and Gynaecology 1997; 11: 431-435.
16. Zoller B, Holm J & Dahlback B. Resistance to activated protein C due to a factor V gene mutation: the most common inherited risk factor of thrombosis. Trends in Cardiovascular Medicine 1996; 6: 45.
17. Margaglione M, Bossone A, Coalizz D et al. FV HR2 haplotype as additional inherited risk factor for deep venous thrombosis in individuals with a high risk profile. Thrombosis & Haemostasis 2002; 87: 32-36.
18. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 2000; 356: 182-183.
19. Poort SR, Rosendaal FR, Reitsma PH & Bertina RM. A common genetic variation in the three untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698.
20. McColl MD, Ellison J, Reid F et al. Prothrombin 20210GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. British Journal of Obstetrics & Gynaecology 2000; 107: 567-569.
21. McColl MD, Walker ID & Greer IA. A mutation in the prothrombin gene contributing to venous thrombosis in pregnancy. British Journal of Obstetrics & Gynaecoiogy 1998; 105: 923-925.
22. Zheng H, Tzeng CC, Butt C et al. An extremely low prevalence of factor V Leiden, FIIG20210A and FXIIIV34L in Taiwan Chinese population. Thrombosis & Haemostasis 2002; 87: 1081-1082.
23. Den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. New England Journal of Medicine 1998; 334(12): 759-762.
24. Greer IA. The challenge of thrombophilia in maternal-fetal medicine. New England Journal of Medicine 2000; 342: 424-425.
25. Gerhardt A, Scharf RE, Beckman MW et al. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium. New England Journal of Medicine 2000; 342: 374-380.
26. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999; 353: 1258-1265.
27. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
28. Conard J, Horellou MH, van Dreden P et al. Thrombosis in pregnancy and congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thrombosis & Haemostasis 1990; 63: 319-320.
29. Study Group on Natural Inhibitors & Pabinger I. Thrombotic risk in hereditary anti-thrombin III, protein C or protein S deficiency. Arteriosclerosis Thrombosis and Vascular Biology 1996; 16: 742-748.
30. De Stefano Y, Leone G, Masterangela S et al. Thrombosis during pregnancy and surgery in patients with congenital deficiency of anti-thrombin III, protein C-protein S. Thrombosis & Haemostasis 1994; 71: 799-800.
31. Middeldorp S, van der Meer J, Hamulyak K & Buller H. Counselling women with factor V Leiden homozygosity: use absolute instead of relative risks. Thrombosis & Haemostasis 2001; 87: 360-361.
32. Martinelli I, de Stefano V, Taioli E et al. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thrombosis & Haemostasis 2002; 87: 791-795.
33. Clark P, Twaddle S, Walker ID et al. Screening for the factor V Leiden mutation in pregnancy is not cost effective. Lancet 2002; 359: 1919-1920.
34. Bates SM & Ginsberg JS. Anticoagulants in pregnancy: fetal defects. Baillière's Clinical Obstetrics and Gynaecology 1997; 11: 479-488.
35. Vitale N, De Feo M, De Santo LS et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. Journal of the American College of Cardiology 1999; 33: 1642-1645.
36. Flessa HC, Klapstrom AB, Glueck MJ et al. Placental transport of heparin. American Journal of Obstetrics & Gynecology 1965; 93: 570-573.
37. Letsky E. Peripartum prophylaxis of thromboembolism. Baillière's Clinical Obstetrics and Gynaecology 1997; 11: 523-543.
38. Forestier F, Daffos F & Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thrombosis Research 1984; 34: 557-560.
39. Forestier F, Daffos F, Rainaut M et al. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thrombosis & Haemostasis 1987; 57: 234.
40. Sanson BJ, Lensing AWA, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thrombosis & Haemostasis 1999; 81: 668-672.
41. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillière's Clinical Obstetrics and Gynaecology 1997; 11: 489-490.
42. Pettila V, Leinonen P, Markkola A et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis & Haemostasis 2002; 87: 182-186.
43. Warkentin TE, Levine MN, Hirsh J et al. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. New England Journal of Medicine 1995; 332: 1330-1335.
44. Nelson-Piercy C, Letsky EA & de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. American Journal of Obstetrics & Gynecology 1997; 176: 1062-1068.
45. Greer IA. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology. Baillière's Clinical Obstetrics and Gynaecology 1997; 11: 403-430.
46. Ellison J, Walker ID & Greer IA. Antifactor Xa profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin for prevention and treatment of thromboembolism in pregnancy. British Journal of Obstetrics & Gynaecology 2000; 107: 1116-1121.
47. Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. British Journal of Obstetrics & Gynaecology 2001; 108: 1134-1140.
48. Hunt BJ, Doughty HA, Majumdar G et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thrombosis & Haemostasis 1997; 77: 39-43.
49. Blomback M, Bremme K, Hellgren M et al. Thromboprophylaxis with low molecular mass heparin, Fragmin (dalteparin), during pregnancy - longitudinal safety study. Blood Coagulation & Fibrinolysis 1998; 9: 1-9.
50. Barbier P, Jongville AR, Autre TE & Coureau C. Fetal risks with dextran during delivery. Drug Safety 1992; 7: 71-73.
51. Lindoff-Last E, Willeke A, Thalhammer C et al. Hirudin treatment in a breastfeeding woman. Lancet 2000; 355: 467-468.
52. Macklon NS & Greer IA. Technical note: compression stockings and posture - a comparative study of their effects on the proximal deep veins in the leg at rest. British Journal of Radiology 1995; 68: 515-518.
53. Clagett GP, Anderson FA & Geerts W. Prevention of venous thromboembolism. Chest 1998; 114: 521S-560S.
54. CLASP Collaborative Group, CLASP: a randomised trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619-629.
55. Imperiale TF & Petrulis AS. A meta-analysis of low-dose aspirin for prevention of pregnancy-induced hypertensive disease. Journal of the American Medical Association 1991; 266: 260-264.
56. De Swiet M, Floyd E & Letsky E. Low risk of recurrent thromboembolism in pregnancy (letter). British Journal of Hospital Medicine 1987; 38: 264.
57. Ginsberg J, Greer IA & Hirsh J. Sixth ACCP consensus conference on antithrombotic therapy. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-131S.
58. Howell R, Fidler J, Letsky E et al. The risk of antenatal subcutaneous heparin prophylaxis: a controlled trial. British Journal of Obstetrics & Gynaecology 1983; 90: 1124-1128.
59. Badaracco MA & Vessey M. Recurrent venous thromboembolic disease and use of oral contraceptives. British Medical Journal 1974; 1: 215-217.
60. Tengborn L. Recurrent thromboembolism in pregnancy and puerperium: is there a need for thromboprophylaxis? American Journal of Obstetrics & Gynecology 1989; 160: 90-94.
61. Brill-Edwards P & Ginsberg JS. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism. New England Journal of Medicine 2000; 343: 1439-1444. Authors for the Recurrence Of Clot In This Pregnancy (ROCIT) Study Group.
62. Scottish Intercollegiate Guidelines Network, Prophylaxis of venous thromboembolism. A national clinical guideline. Edinburgh, 2002.
63. Checketts MR & Wildsmith JAW. Central nerve block and thromboprophylaxis - is there a probem? British Journal of Anaesthesia 1999; 82: 164-167.
64. Horlocker TT & Wedel DJ. Spinal and epidural blockade and perioperative low molecular weight heparin: smooth sailing on the Titanic. Anaesthesia Analgesia 1998; 86: 1153-1156.
65. http://www.asra.com/items_of_interest/consensus_statements/ (current website with consensus statement on anticoagulants and neuraxial anaesthesia from the American Society of Regional Anesthesia).
66. Hirsh J & O'Donnell MJ. Venous thromboembolism after long flights: are airlines to blame? Lancet 2001; 357: 1461-1462.
67. Ferrari E, Chevallier T, Chapelier A & Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest 1999; 115: 440-444.
68. Kraaijenhagen RA, Haverkamp D, Koopman MM et al. Travel and risk of venous thrombosis. Lancet 2000; 356: 1492-1493.
69. RCOG, Advice on preventing deep vein thrombosis for pregnant women travelling by air. Scientific Advisory Committee Opinion Paper I, London: RCOG Press, 2001.
70. Scurr JH, Machin SJ, Bailey-King S et al. Frequency and prevention of symptomless deep-vein thrombosis in long-haul (four hours) flights: a randomised trial. Lancet 2001; 357: 1485-1489.